US Patent 9,101,637: Scope, Claim Architecture, and Patent Landscape for NSAID-in-Oil Lecithin Complexes
US 9,101,637 claims a single core use technology: reducing gastrointestinal (GI) toxic effects of an NSAID by administering the NSAID as an “NSAID-in-oil suspension” where the oil phase is a lecithin oil with a defined composition range for phosphatidylcholine (PC) and other lecithin-derived components, and where the NSAID is in an association complex with the phospholipid of that lecithin oil. Dependent claims narrow GI endpoints to bleeding and ulceration and specify NSAIDs (aspirin, indomethacin, ibuprofen) and example disease contexts.
What does the independent claim actually require?
Claim 1 is the operative scope. It is written as a method claim with a precise formulation construction and two functional/legal anchors (GI toxic effect reduction; NSAID association complex).
Claim 1 elements (all required)
-
Method purpose / outcome
- “reducing a GI toxic effect” in a subject who ingests the NSAID.
-
Drug administration form
- administering “the NSAID” as an “NSAID-in-oil suspension.”
- the suspension comprises:
-
Lecithin oil identity and composition constraints
- lecithin oil consists of:
- soy lecithin components in sunflower oil
- lecithin oil has about the following weight percent composition:
- PC: 33 to 40 wt. %
- triglycerides: 26 to 31 wt. %
- free fatty acids: 8 to 13 wt. %
- glycolipids: 5 to 9 wt. %
-
Association-complex requirement
- “wherein the NSAID is in an association complex with a phospholipid of the lecithin oil.”
Practical meaning for scope
- The claim is not just “NSAID with lecithin oil.” It requires:
- a specific lecithin oil made from soy lecithin in sunflower oil; and
- quantified compositional ranges; and
- an association complex between the NSAID and a phospholipid component of the lecithin oil.
Any design-around that changes oil identity, component sources, or compositional ranges risks falling outside Claim 1. A competitor can still pursue relief from GI toxicity with lecithin-based systems, but literal coverage hinges on these exact formulation and association features.
How broad is coverage across GI toxicity and patient populations?
GI toxic effect scope (Claim 2)
- Claim 2 narrows Claim 1 by defining the GI toxic effect as:
- at least one of:
- GI bleeding
- GI tract ulceration
Coverage implication
- Claim 1 covers “GI toxic effect” generally; Claim 2 selects two specific endpoints.
- For enforcement, an accused method can target either claim depending on how infringement is argued and what endpoints were tested/expected.
Disease/condition scope (Claims 6-7)
Claim 6 expands the subject “suffers from” list, where the subject has at least one condition selected from:
- tissue inflammation
- tissue ulceration
- pain
- fever
- cardiovascular disease
- ovarian cancer
- colon cancer
- Alzheimer’s Disease
Claim 7 further narrows Claim 6 to:
Coverage implication
- These claims are not limited to ulcer disease or GI patients. They cover broad therapeutic contexts where NSAIDs are used.
- This matters for portfolio risk because competitors often position NSAID formulations for anti-inflammatory, analgesic, and anti-cancer adjunct uses; Claim 6’s list includes both cardiovascular disease and colon cancer/ovarian cancer.
Which NSAIDs are covered?
Dependent claims specify a closed set
Coverage implication
- Literal protection for the specified formulation architecture is limited to these three NSAIDs (within the dependent claim strategy).
- The independent Claim 1 says “the NSAID” without limiting identity, but in practice infringement analyses often tie to specific examples and claim dependencies. If an accused product uses an NSAID outside that set, Claim 3-5-8 would not be available, but Claim 1 may still be asserted depending on how “NSAID” is interpreted in the patent’s context (and the patent specification’s support).
What is the claim construction risk around “association complex”?
Claim 1 requires: “NSAID is in an association complex with a phospholipid of the lecithin oil.”
This introduces a potential contention point:
- Whether “association complex” is satisfied by:
- non-covalent association (electrostatic/hydrophobic),
- salt formation,
- micellar embedding,
- or co-dissolution/adsorption.
For scope, the safest reading for enforcement is that the NSAID is physically associated with the phospholipid fraction as part of the formulation. For competitors, the safest design-around is to formulate a system where the NSAID is simply suspended or dissolved in the oil matrix without forming a meaningful association with the phospholipid fraction.
How would a competitor design around Claim 1?
Given Claim 1’s hard constraints, the most direct design paths are:
1) Change the lecithin oil composition ranges
Claim 1 defines weight percent windows for PC, triglycerides, free fatty acids, and glycolipids. Shifting outside any window provides an argument for non-infringement.
| Claim 1 component |
Required range (wt. %) |
Design-around approach |
| Phosphatidylcholine (PC) |
33 to 40 |
Use a lecithin oil composition with lower/higher PC fraction |
| Triglycerides |
26 to 31 |
Adjust refining/processing to shift triglyceride content |
| Free fatty acids |
8 to 13 |
Use different fractionation or processing |
| Glycolipids |
5 to 9 |
Use lecithin oil source/processing that yields different glycolipid content |
2) Change lecithin source or oil carrier
Claim 1 requires “soy lecithin components in sunflower oil.” Changing:
- soy to another lecithin source (for example, sunflower or egg-derived lecithin components), or
- sunflower oil carrier to another oil carrier,
creates a literal mismatch for the “consists of” requirement.
3) Use a lecithin oil but remove the “association complex”
A competitor could attempt to:
- suspend NSAID in the oil without phospholipid association,
- or use phospholipid-free oil formulations,
- or replace the phospholipid fraction with non-phospholipid surfactants.
Because Claim 1 ties the NSAID to “an association complex with a phospholipid,” this is a key technical pivot.
4) Avoid the formulation “NSAID-in-oil suspension” characterization
If a competitor uses a different dosage form (emulsion, solid dispersion, enteric coating, tablet), and can argue it is not an “NSAID-in-oil suspension,” literal coverage weakens. The claim does not define particle size or viscosity; still, dosage form labeling and composition can matter in infringement analysis.
What does the claim strategy imply for enforcement and validity posture?
Enforcement leverage
Claim 1 is a method with a narrow formulation definition:
- If a product uses the defined lecithin oil composition and yields an NSAID-phospholipid association complex, that product’s prescribing and administration workflows can be targeted.
Litigation vulnerabilities
The more precise the formulation parameters, the narrower the literal claim. That can help competitors, but it also gives the patentee a strong technical fingerprint when the accused product is known.
Claim-by-claim scope map
| Claim |
Scope focus |
Main limiting feature |
| 1 |
GI toxicity reduction method |
NSAID administered as NSAID-in-oil suspension with defined soy lecithin in sunflower oil composition and NSAID-phospholipid association complex |
| 2 |
GI toxicity endpoints |
GI bleeding and/or GI tract ulceration |
| 3 |
NSAID identity set |
aspirin, indomethacin, ibuprofen |
| 4 |
Aspirin specific |
aspirin |
| 5 |
Ibuprofen specific |
ibuprofen |
| 6 |
Subject condition set |
inflammation, ulceration, pain, fever, cardiovascular disease, ovarian cancer, colon cancer, Alzheimer’s disease |
| 7 |
Cardiovascular disease specific |
cardiovascular disease |
| 8 |
Indomethacin specific |
indomethacin |
US patent landscape: where similar ideas tend to cluster
Without the patent’s full specification, file history, cited references, or a numbered family member list, a complete “interlocking” landscape cannot be constructed. However, the claim architecture itself signals the likely landscape features that matter for freedom-to-operate (FTO):
1) Likely adjacent families: lecithin-based GI protection systems
Patents in this area typically cluster around:
- GI protection when using NSAIDs,
- lipid-based formulations (oil suspensions, emulsions, micelles),
- phospholipid interactions and delivery vehicles.
US 9,101,637’s defining element is the lecithin oil composition definition paired with an association complex requirement.
2) Likely competing technologies: enteric coatings and COX-sparing approaches
Many NSAID GI protection solutions in the US landscape do not rely on lecithin oil association complexes, including:
- enteric coatings,
- prodrugs,
- COX-2 selective inhibitors,
- combination therapies (NSAID plus gastroprotective agents).
Those may avoid Claim 1’s formulation limitations even if they target GI endpoints.
3) Likely formulation differentiation: phospholipid identity and oil source
Because Claim 1 locks:
- soy lecithin components,
- sunflower oil carrier,
- and PC/triglyceride/free fatty acid/glycolipid ranges,
the most relevant infringement comparison in practice is between:
- lecithin oils with similar component profiles,
- manufactured with similar fractionation,
- and used to form NSAID-phospholipid association complexes.
Business impact: where risk concentrates
Highest literal infringement probability
- Products or clinical protocols that:
- use soy lecithin-derived sunflower-oil lecithin oil with PC 33 to 40 wt. %,
- maintain triglycerides 26 to 31 wt. %,
- and explicitly form an NSAID association complex with phospholipid.
Moderate risk
- Products that use lecithin oils but:
- lack compositional breakdown data,
- use different oil carriers,
- use different lecithin sources,
- or do not characterize phospholipid association.
Lower literal risk
- Systems that address GI toxicity via:
- enteric coatings,
- systemic gastroprotective co-therapy,
- COX selectivity,
- or non-lecthin formulation architectures.
Key Takeaways
- US 9,101,637 Claim 1 is a method requiring a very specific formulation: NSAID delivered as an “NSAID-in-oil suspension” with soy lecithin components in sunflower oil and with tight compositional windows for PC, triglycerides, free fatty acids, and glycolipids.
- Coverage also requires the NSAID to be in an association complex with a phospholipid of that lecithin oil.
- Dependent claims narrow GI endpoints to GI bleeding and GI ulceration, specify NSAIDs to aspirin, indomethacin, ibuprofen, and broaden the subject context to multiple inflammation/pain/cancer/CV/Alzheimer’s scenarios.
- For competitors, the most direct design-around levers are the oil identity, lecithin oil composition ranges, and whether an NSAID-phospholipid association complex is formed as part of the administered dosage form.
FAQs
1) Does the patent cover any GI toxicity or only bleeding and ulceration?
Claim 1 covers “GI toxic effect” generally. Claim 2 narrows that to GI bleeding and/or GI tract ulceration.
2) Are only aspirin, indomethacin, and ibuprofen covered?
Claims 3-5-8 expressly limit the NSAID to aspirin, indomethacin, and ibuprofen. Claim 1 uses broader language (“the NSAID”) but the dependent claim strategy is limited to that set.
3) What lecithin oil composition ranges matter most?
PC must be about 33 to 40 wt. %, triglycerides 26 to 31 wt. %, free fatty acids 8 to 13 wt. %, and glycolipids 5 to 9 wt. %, using soy lecithin components in sunflower oil.
4) What does “association complex” change for scope?
It adds a technical requirement beyond merely mixing NSAID with lecithin oil. It requires the NSAID to be associated with a phospholipid component of the lecithin oil.
5) What patient conditions are contemplated by the claim set?
Claim 6 lists inflammation, ulceration, pain, fever, cardiovascular disease, ovarian cancer, colon cancer, and Alzheimer’s Disease; Claim 7 further narrows to cardiovascular disease.
References (APA)
[1] US Patent 9,101,637. “Method of reducing gastrointestinal toxic effect of NSAIDs using NSAID-in-oil suspension containing lecithin oil with defined composition and NSAID-phospholipid association complex.”
